Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Marques-Pamies, Montserrat, Gil, Joan, Valassi, Elena, Hernández García, Marta, Biagetti, Betina, Giménez-Palop, Olga, Martínez, Silvia, Carrato, Cristina, Pons, Laura, Villar-Taibo, Rocío, Araujo-Castro, Marta, Blanco, Concepción, Simón, Inmaculada, Simó-Servat, Andreu, Xifra, Gemma, Vázquez, Federico, Pavón, Isabel, García-Centeno, Rogelio, Zavala, Roxana, Hanzu, Felicia A, Mora, Mireia, Aulinas, Anna, Vilarrasa, Nuria, Librizzi, Soledad, Calatayud, María, de Miguel, Paz, Alvarez-Escola, Cristina, Picó Alfonso, Antonio M, Sampedro, Miguel, Salinas, Isabel, Fajardo-Montañana, Carmen, Cámara, Rosa, Bernabeu Morón, Ignacio, Jordà, Mireia, Webb, S. M, Marazuela, Mónica, Puig Domingo, Manuel, Universitat Autònoma de Barcelona
Format: Artikel
Sprache:eng
Schlagworte:
Acromegaly
Acute octreotide test
Individualized treatment
Precision medicine
Prediction
Somatostatin analogs
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2). A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs' response. Those patients whose IGF1 decreased to